Akebia Therapeut Stock Price, News & Analysis

Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to two newly hired employees on January 30, 2026, covering an aggregate of 132,675 shares. The options carry a $1.41 exercise price (equal to the closing price on the grant date), vest over four years and have a 10-year term.

The awards were made under Akebia’s inducement award program in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms of the stock option agreements and continued service.

Akebia Therapeutics (Nasdaq: AKBA) provided 2026 corporate updates focused on Vafseo commercial progress and its mid‑stage rare kidney disease pipeline. The company said it has prescribing access covering ~275,000 dialysis patients, completed enrollment in the Phase IV VOICE trial (>2,100 patients) with topline results expected in early 2027, and enrolled ~350 patients in VOCAL with data expected in Q4 2026. Akebia reported Q4 2025 Vafseo net product revenue expectation of $5–$6 million (impacted by a $4.5–$5 million channel inventory reduction) and said revenue growth is expected to resume in Q1 2026. Pipeline updates include first patient dosed in praliciguat Phase 2 for FSGS (Dec 2025) and a planned AKB-097 Phase 2 basket trial starting 2H 2026 with initial data expected in 2027.

Akebia Therapeutics (Nasdaq: AKBA) announced that the first patient has been dosed in a Phase 2 randomized, double-blind, placebo-controlled study of oral once-daily praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS).

The study will randomize ~60 adults on maximally tolerated ACEi/ARB therapy 1:1 to praliciguat or placebo for a 24-week double-blind period followed by a 24-week open-label extension. The primary endpoint is change in urine protein-to-creatinine ratio (UPCR) at Week 24; a key secondary endpoint is partial remission defined as 40% UPCR reduction and UPCR <1.5 g/g.

Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to a newly hired employee on December 31, 2025 under Nasdaq Listing Rule 5635(c)(4).

The grant covers 197,900 options with an exercise price of $1.61 per share (equal to the closing price on the grant date). Options vest over four years (25% on the first anniversary, then quarterly thereafter), each option has a 10-year term, and awards are subject to Akebia’s inducement award program and a stock option agreement.

Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to two newly hired employees on November 28, 2025 under Nasdaq Listing Rule 5635(c)(4).

The awards total 22,576 options with an exercise price of $1.58 per share (equal to the closing price on the grant date). Options vest over four years (25% at the first anniversary, then quarterly vesting for the remaining 75%), have a 10-year term, and are governed by Akebia’s inducement award program and stock option agreement.

Akebia (Nasdaq: AKBA) announced the establishment of a rare kidney disease pipeline on Dec 1, 2025, centered on two candidates: AKB-097 (a tissue-targeted C3d‑Factor H fusion protein complement inhibitor acquired from Q32 Bio) and praliciguat (an sGC stimulator).

Akebia acquired all rights to AKB-097 and says it targets complement activation sites without expected systemic complement inhibition. A Phase 2 trial of praliciguat in FSGS has been initiated, and both Phase 2 programs are planned to begin treating subjects in 2026. Akebia expects AKB-097 Phase 2 basket trial data beginning in 2027.

Q32 Bio (NASDAQ:QTTB) sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics (NASDAQ:AKBA) for $12 million in upfront and near-term payments and is eligible for up to $592 million in total milestone payments plus tiered royalties.

Q32 received $7M at signing, $3M at six months, and $2M by end of 2026 or upon an earlier milestone. The company says proceeds and existing cash are expected to extend its runway into the second half of 2027 while it advances bempikibart and SIGNAL-AA Part B topline data is on track for mid-2026. Q32 retains its tissue-targeted complement platform, including ADX-096, and is evaluating strategic options for remaining programs.

Akebia Therapeutics (Nasdaq: AKBA) said its executive team will participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:30 PM ET in New York City.

The company said a webcast of the presentation will be available after the conference via the Investors section at https://ir.akebia.com. The Piper Sandler conference runs December 2–4, 2025.

Akebia (Nasdaq: AKBA) reported Q3 2025 results and operational updates for Vafseo (vadadustat). Total revenues were $58.8 million in Q3 2025 versus $37.4 million in Q3 2024. Vafseo net product revenue was $14.3 million in Q3 2025; Auryxia net product revenue was $42.5 million.

Prescribing access across the customer base reached 60,000 patients by end of Q3 and is expected to grow to 275,000 patients by year-end. A DaVita operational pilot at >100 clinics is expected to complete in November 2025. A post-hoc INNO2VATE analysis presented at ASN Kidney Week showed a statistically more favorable composite of all-cause mortality and hospitalization for vadadustat versus ESA.

Q3 net income was $0.5 million versus a $20.0 million loss year-ago; cash and cash equivalents were $166.4 million as of September 30, 2025.